Brean Capital Remains Bullish on Horizon Pharma (HZNP) Following 2Q Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Horizon Pharma plc Names George Hampton Executive Vice President, Global Orphan Business Unit and International Operations
August 7, 2015 4:05 PM EDTDUBLIN, IRELAND -- (Marketwired) -- 08/07/15 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today named George Hampton as executive vice president, global orphan business unit and international operations, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. Hampton has also joined the Horizon's Executive Committee.
"As we begin to enter the European and other international markets anchored by the potential near-term approval of RAVICTI,... More
Horizon Pharma plc Announces Record Second Quarter 2015 Financial Results
August 7, 2015 7:00 AM EDTDUBLIN, IRELAND -- (Marketwired) -- 08/07/15 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its second-quarter 2015 financial results today.
Quarterly Financial Highlights
(in millions except for per share amounts and % % percentages) Q2 15 Q2 14 Change 1H 15 1H 14 Change ------- ------- ------ ------- ------- ------ Net sales $ 172.8 $ 66.1 161 $ 286.0 $ 118.0 142 Net income (loss) 31.8 (27.8) NM 12.3 (234.0) NM Adjusted non-GAAP net income 61.9 19.8 213 86.4 26.8 222 Adjusted EBITDA 76.1 21.5 254 108.5 30.2 259 Earnings (loss) per share - basic $ 0.21 $ (0.38) NM $ 0.09 $ (3.34) NM Adjusted non-GAAP earnings per share - basic 0.41 0.27 52 0.62 0.38 63 Earnings (loss)... More
Depomed Sends Letter to Horizon Pharma
August 7, 2015 6:30 AM EDTNEWARK, Calif., Aug. 7, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company") today announced that it has sent the following letter to Horizon Pharma plc (NASDAQ: HZNP) ("Horizon"):
August 7, 2015
Timothy P. Walbert Chairman of the Board, President and Chief Executive OfficerHorizon Pharma plcConnaught House, 1st Floor, 1 Burlington Road Dublin 4, IrelandÂ
Dear Tim, Â
In our... More
